

DRAFT PROGRAMME

24–26 October | Lisboa Congress Centre, Portugal

DAY 1 TUESDAY 24 OCTOBER

08:00 **Arrival and registration**

09:00 – 10:00 INAUGURAL SESSIONS

Science to policy

Chair: *Alison Ritter, Australia*

Henrietta Bowden-Jones, Imperial College London, United Kingdom
Alexandre Quintanilha, Chair, Parliamentary Commission on Education and Science, Portugal
Jallal Toufiq, The Moroccan Observatory on Drugs and Addiction, Morocco

Policy to science

Chair: *Werner Sipp, Germany*

Chloé Carpentier, United Nations Office on Drugs and Crime
Torbjorn Brekke, Pompidou Group
Vladimir Poznyak, World Health Organization
Floriana Sipala, European Commission

10:00 – 10:30 PLENARY SESSION I (FEEDBACK FROM INAUGURAL SESSIONS)

Chairs: *Alexis Goosdeel, EMCDDA and João Goulão, SICAD*

Alison Ritter, National Drug and Alcohol Research Centre, Australia
Werner Sipp, Former President International Narcotics Control Board, Germany

10:30 – 11:00 **Opening ceremony**

11:00 – 11:30 **Coffee break**

11:30 – 13:00 **PARALLEL SESSIONS** (see separate document for poster sessions)

PAPER SESSION 1 Alcohol - informing prevention and policy	PAPER SESSION 2 The measurement of problems and trends	PAPER SESSION 3 A focus on pharmacotherapy	PAPER SESSION 4 Ageing and intergenerational issues	PAPER SESSION 5 Gambling - behavioural insights
<ul style="list-style-type: none"> – Law of alcohol. Two sides of the coin: consumers and retailers. <i>Elsa Lavado, Portugal</i> – Alcohol marketing: how to regulate? A comparative analysis. <i>Marieke Vlaemyck, Belgium</i> – Attitudes towards alcohol policy across Europe, results of the RARHA seas study. <i>Zsuzsanna Elekes, Poland</i> – alcohol marketing in Portugal: alcohol industry and government strategies in the 21st century. <i>Hilson Cunha Filho, Portugal</i> – Alcohol and illegal drugs: estimating social cost in Catalonia. <i>Vincenzo Alberto Vella, Spain</i> – Alcohol and other drug use among the working population in Belgium: prevalence and job related consequences. <i>Marie-Claire Lambrechts, Belgium</i> 	<ul style="list-style-type: none"> – Measuring problematic cannabis use in the general population: conception, use and future of the cannabis abuse screening test (CAST). <i>Stéphane Legleye, France</i> – Changes in cultural patterns of drugs use throughout three generations of the Portuguese population - 1950, 1975 and 2000. <i>Casimiro Balsa, Portugal</i> – Cannabis epidemic or return of opioid problems or decrease of high risk drug use among young adults in Austria. <i>Martin Busch, Austria</i> – Longitudinal trajectories of polydrug use among adolescents: two years follow-up. Víctor <i>Martínez-Loredo, Spain</i> – Treatment demand indicator: experience of its implementation in Nigeria. <i>Dominique Lopez, India</i> 	<ul style="list-style-type: none"> – Patient centered care for injectable opioid assisted treatment. <i>Kirsten Marchand, Canada</i> – Orienting the appropriate treatment of pain in detained drug users: indications from a retrospective study. <i>Felice Nava, Italy</i> – Response to treatment among indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomized controlled trial for the treatment of long-term opioid-dependence. <i>Heather Palis, Canada</i> – The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Ontario, <i>Canada. Joseph Eibl, Canada</i> – The effects of prescribing varenicline on longer-term health outcomes: an observational cohort study using electronic medical records. <i>Kyla Thomas, United Kingdom</i> – Exploration of the benefits of methadone treatment for dual users of heroin and crack who inject or have previously injected drugs - preliminary findings. <i>Felicia Heidebrecht, United Kingdom</i> – SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy. <i>Jason Grebely, Australia</i> 	<ul style="list-style-type: none"> – Opioid treatment outcomes in older adults: a review of the literature. <i>Anne Marie Carew, Ireland</i> – Mortality and causes of death in an ageing Norwegian OMT cohort. <i>Ivar Skeie, Norway</i> – Case management for older drug users. <i>Martin Schmid, Germany</i> – Ageing drug users a new challenge for drug treatment programmes in Slovenia. <i>Milan Krek, Slovenia</i> – Explanations for intergenerational transference of addiction: perspective of the person with parent(s) who suffer from addiction. <i>Margreet van der Meer, Netherlands</i> – Children of parents who use substance: parents who use and grandparents who care, perspectives of needs, risks and protective factors. <i>Karen Galligan, Ireland</i> 	<ul style="list-style-type: none"> – Problem gambling in adolescence: an analysis conducted from the actor's perspective. <i>Annie-Claude Savard, Canada</i> – Factors contributing to the normalisation of gambling: a qualitative study of international gambling experts. <i>Samantha Thomas, Australia</i> – How do gambling products which are provided in 'family friendly' venues, shape young people's gambling consumption intentions? A qualitative study of children in Australia. <i>Amy Bestman, Australia</i> – Emotional characteristics of gamblers' relatives. <i>Paula Jauregui, Spain</i> – Female pathological gamblers: characteristics and obstacles for treatment. <i>Andrea Wöhr, Germany</i> – Online sports betting advertising and gambling disorder: a content analysis approach. <i>Hibai Lopez-Gonzalez, United Kingdom</i>

STRUCTURED SESSION 1 Social cognition and interaction in substance addiction Chair: <i>Boris Quednow, Switzerland</i> Co-Chair: <i>Antonio Verdejo-Garcia, Australia</i>	STRUCTURED SESSION 2 Understanding the clinical toxicology of novel psychoactive substances (NPS) Chair: <i>David Wood, United Kingdom</i>	STRUCTURED SESSION 3 The Portuguese decriminalisation model: a comprehensive approach Chair: <i>Sofia Albuquerque, Portugal</i>	STRUCTURED SESSION 4 Setting standards in the addiction field: a view from Europe Chair: <i>Antoni Gual, Spain</i> Co-Chair: <i>Geert Dom, Belgium</i>	STRUCTURED SESSION 5 Symposium on the future of addiction research: an overview Chair: <i>Robert West, United Kingdom</i>
<ul style="list-style-type: none"> – Dose-related effects of methamphetamine use on social cognition. <i>Antonio Verdejo-Garcia, Australia</i> – Mind-reading impairment in crack-cocaine users: an fMRI study of the moderator effects of early life stress. <i>Rodrigo Grassi-Oliveira, Brazil</i> – Emotion, alcohol and addiction. <i>Salvatore Campanella, Belgium</i> – Compassion and social cognition in heroin users: describing deficits and developing treatments. <i>Charles Morgan, United Kingdom</i> – Effects of non-medical prescription opioid use on social cognition and social pain. <i>Sara Kroll, Switzerland</i> 	<ul style="list-style-type: none"> – Details to be confirmed. 	<ul style="list-style-type: none"> – Decriminalisation Policy and the role of the Commissions for the Dissuasion of Drug Addiction. <i>Américo Gegaloto, Portugal</i> – Guidelines for Dissuasion Intervention: an health and preventive approach. <i>Raquel Lopes, Portugal</i> – The Dissuasion intervention at the Commissions for the Dissuasion of Drug Addiction of Porto, priority groups and the role of external stakeholders. <i>Purificação Anjos, Portugal</i> – Portuguese Commissions for the Dissuasion of Drug Addiction: perspectives of indicted drug users on their role in drug use. <i>Ludmila Carapinha, Portugal</i> – Drug users' assessment of the enforcement of Portuguese drug decriminalisation law and predictors of drug use. <i>Jorge Quintas, Portugal</i> 	<ul style="list-style-type: none"> – An empirical basis to diagnose gambling and gaming disorders in ICD-11. <i>Karl Mann, Germany</i> – An overview of European Addiction Clinical guidelines. <i>Connor Farren, Ireland</i> – The legal status of medical and recreational use of cannabis throughout Europe. <i>Jørgen Bramness, Norway</i> 	<ul style="list-style-type: none"> – Symposium: <i>John Holmes, United Kingdom</i> <i>Joanne Neale, United Kingdom</i> <i>Felix Naughton, United Kingdom</i> <i>John Marsden, United Kingdom</i> – Titles to be confirmed.

12:45 – 14:15 SPONSORED SESSIONS

Lunch boxes available between 13:00 and 14:30

13:15 – 14:15 **PARALLEL SESSIONS** (see separate document for poster sessions)

PAPER SESSION 6 Concepts and constructs	PAPER SESSION 7 Drug use and infectious diseases: reviewing the evidence	PAPER SESSION 8 NPS - a challenge for responses	PAPER SESSION 9 Inequalities
<ul style="list-style-type: none"> – A transdiagnostic dimensional approach to addiction: an international Delphi consensus study. <i>Murat Yücel, Australia</i> – Putting the brain in its place: arguments from ethics and philosophy of science. <i>Jaakko Kuorikoski and Susanne Uusitalo, Finland</i> – Non problematic illicit drug use: a less known but not less important phenomenon. <i>Olga Cruz, Portugal</i> – Constructing alcohol-related problems – attitudes of social workers and their clients. <i>Elina Renko, Finland</i> 	<ul style="list-style-type: none"> – Injecting and sexual risk-taking amongst people who inject drugs: a global review. <i>Amy Peacock, Australia</i> – Needle syringe programmes and opioid substitution therapy for prevention HCV transmission among people who inject drugs: Cochrane systematic review. <i>Matthew Hickman, United Kingdom</i> – Recent incarceration and risk of hepatitis C and HIV transmission amongst people who inject drugs: a systematic review and meta-analysis. Jack Stone, United Kingdom – A systematic review and meta-analysis of psychosocial interventions to reduce drug and sexual blood borne virus risk behaviours among people who inject drugs. <i>Gail Gilchrist, United Kingdom</i> – HIV prevention, treatment and care for people who inject drugs: a systematic review of coverage of interventions. <i>Sarah Larney, Australia</i> 	<ul style="list-style-type: none"> – The German new psychoactive substance law (NPSG): perceived and expected outcomes in the first stage of implementation. <i>Tessa-Virginia Hannemann, Germany</i> – French media and new psychoactive substances: is a new discourse emerging. <i>Julie-Emilie Adès, France</i> – New psychoactive substances: current health-related practices and challenges in responding to use and harms in Europe. <i>Alessandro Pirona, EMCDDA</i> – Responses to the problem of ‘legal highs’ in Poland and their consequences. <i>Krzysztof Krajewski, Poland</i> 	<ul style="list-style-type: none"> – A review of the factors associated with mothers who use substances losing care of their children. <i>Martha Canfield, United Kingdom</i> – Social determinants of drug-related mortality among general population. <i>Sanna Rönkä, Finland</i> – Boxing clever: evaluation of a community based inter-agency education and fitness substance use intervention program. <i>Sarah Morton, Ireland</i> – The representation of non-Belgians in national drug treatment. <i>Eva Blomme, Belgium</i> – Understanding addiction: a health inequalities and social harms perspective. <i>Aileen O’Gorman, United Kingdom</i>
STRUCTURED SESSION 6 European quality standards in drug demand reduction: how to monitor implementation? Chair: <i>Marica Ferri, EMCDDA</i>	STRUCTURED SESSION 7 Assessment of risky cannabis use and related consequences Chair: <i>Hugo López Pelayo, Spain</i>	STRUCTURED SESSION 8 Gambling and gaming 2.0: one and the same? Chair: <i>Sylvia Kairouz, Canada</i>	STRUCTURED SESSION 9 Global surveillance of prescription drug misuse: multi-system data networks throughout Europe, United Kingdom and North America Chair: <i>Jody Green, United States-Canada</i>
<ul style="list-style-type: none"> – Panel discussion: <i>Matej Kosir, Slovenia</i> <i>Harry Sunmall, United Kingdom</i> <i>Lubomir Okhrulica, Slovak Republic</i> <i>Dave Liddle, Scotland</i> – Titles to be confirmed. 	<ul style="list-style-type: none"> – Definitions of risky and problematic cannabis use: a systematic review. <i>Cristina Casajuana, Spain</i> – Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments. <i>Hugo López-Pelayo, Spain</i> – Standard Joint Unit as a tool for assessing risky cannabis use. <i>Antoni Gual, Spain</i> Discussant: <i>Mercè Balcells, Spain</i> 	<ul style="list-style-type: none"> – Reframing the gambling field: epistemological and methodological shifts in the study of the gambling/gaming convergence. <i>Sylvia Kairouz, Canada</i> – Business models of gaming and gambling and how they converge. <i>Ingo Fiedler, Germany</i> – Overlapping between gambling and some form of gaming in the Internet world: first results of a cross-national survey. <i>Jean-Michel Costes, France</i> 	<ul style="list-style-type: none"> – The evolution of the opioid abuse epidemic in North America. <i>Richard Dart, United States-Canada</i> – The landscape of prescription drug misuse in the U.K. <i>David Wood, United Kingdom</i> – The European experience: prescription drug misuse in France, Germany, Italy and Spain. <i>Jody Green, United States-Canada</i> – Experience of the EURO-DEN Plus: ED presentations with acute toxicity related to misuse of ‘licensed

– Spectrum model of social casino gaming/gambling: Understanding the convergence. *Jennifer Reynolds, Canada*

medicines'. *Paul Dargan, United Kingdom*

14:30 – 16:00 PARALLEL SESSIONS (see separate document for poster sessions)

PAPER SESSION 10 Addressing smoking and related behaviours	PAPER SESSION 11 Alcohol - assessment	PAPER SESSION 12 Addiction - the link with crime and offending	PAPER SESSION 13 Improving responses to HCV
<ul style="list-style-type: none"> – Relative reinforcing efficacy of cigarettes among depressed and non-depressed smokers. <i>Alba González-Roz, Spain</i> – Predicting treatment outcome: an examination of the mechanism of action of two pre-quit smoking cessation pharmacotherapies. <i>Stuart Ferguson, Australia</i> – The efficacy of behavioural activation and contingency management for cigarette smokers with depression: a randomized controlled trial. <i>Alba González-Roz, Spain</i> – Are smoking and e-cigarette use prospectively associated with one another? A longitudinal study of young people in Great Britain. <i>Katherine East, United Kingdom</i> – Individual, interpersonal and environmental risk factors associated with tobacco use [daily smoking] among Kosovar youth. <i>Zamira Hyseni Duraku, Kosovo*</i> – Young adults report increased pleasure from using e-cigarettes and smoking tobacco cigarettes when drinking alcohol. <i>Johannes Thru, United States</i> <p><small>* This designation is without prejudice to positions on status, and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.</small></p>	<ul style="list-style-type: none"> – Validation of alcohol consumption self-reports in the Munich composite international diagnostic interview (M-CIDI). <i>Sören Kuitunen-Paul, Germany</i> – Screening for moderate/high risk alcohol use among opioid dependent patients on buprenorphine maintenance: a clinical and alcohol-biomarker study. <i>Suresh Thapaliya, Nepal</i> – Factors related to binge drinking in adolescence: integrative literature review. <i>Tereza Barroso, Portugal</i> – Context of daily drinking in 18 European countries. Findings of the RARHA seas project. <i>Katarzyna Okulicz-Kozaryn, Poland</i> – Emotion regulation and cognitive control in patients with alcohol dependence. <i>Svetlana Klimanova, Russia</i> – Nunc est bibendum! The effects of placebo and moderate dose alcohol on attentional bias, inhibitory control and subjective craving. <i>Adam McNeill, United Kingdom</i> – Cognitive functioning in patients with abuse of alcohol and intoxicating substances in mood disorders and influence of age on onset substance use. <i>Irma Höjjer, Finland</i> 	<ul style="list-style-type: none"> – Promoting recovery and desistance among primary drug users involved in offending. <i>Charlotte Colman, Belgium</i> – Addiction, comorbidity and criminal recidivism of female systematic offenders. <i>Eric Blaauw, Netherlands</i> – Predicting offending after residential rehabilitation. <i>Birgitte Thylstrup, Denmark</i> – ‘You, of all people’: interviews with ten nurses who lost their medical license due to prescription drug use and theft from the work place. <i>Oda Sjøvoll, Norway</i> – Substance abuse and violent crime: an analysis of the psychopharmacological model in a sample of United States inmates. <i>Michele Pich, United States</i> – ‘If the person doesn’t drink they are one person, if they drink they are another’. How men in treatment for substance use in England and Brazil account for perpetrating intimate partner violence. <i>Polly Radcliffe, United Kingdom</i> 	<ul style="list-style-type: none"> – Factors predicting usage of low dead space syringes amongst people who inject drugs in the United Kingdom, and the association with hepatitis C prevalence. <i>Adam Trickey, United Kingdom</i> – Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the simplify study. <i>Jason Grebely, Australia</i> – Hepatitis Antibody and RNA prevalence among opiate substituted patients in Germany: epidemiological data collected under real life practice circumstances. <i>Bernd Schulte, Germany</i> – Prison history and drug-related problems in people who inject drugs – associations of HIV and HCV with prison history in the European Union and beyond. <i>Lucas Wiessing, EMCDDA</i> – Modelling the impact of interventions targeting high-risk populations on the general hepatitis epidemic in resource-limited settings. <i>Aaron Lim, United Kingdom</i> – Promoting hepatitis C virus (HCV) therapeutic adherence in outreach settings: project evaluation. <i>Teresa Sousa, Portugal</i>

PAPER SESSION 14 Perspectives on policy	PAPER SESSION 15 New psychoactive substances - trends and developments	PAPER SESSION 16 Prevention - theory and practice	PAPER SESSION 17 Integrating care models and partnerships
<ul style="list-style-type: none"> – Evaluating the effect of full legalization on the medical cannabis market in Colorado: implications for prescription policy. <i>Davide Fortin, France</i> – Cyprus national strategy assessment throughout drug treatment services evaluation study: methodology, principal findings and perspectives. <i>Gerasimos Papanastasatos, Greece</i> – Developing an evidence informed local drug strategy: identifying the prevalence, risks and protective factors for children of parents who use drugs. <i>Catherine Comiskey, Ireland</i> – Estimating the current and potential future impact of the Mexican drug law reform on HIV incidence among people who inject drugs (PWID) in Tijuana, Mexico, using mathematical modelling. <i>Annick Borquez, United States</i> – Evaluation of drug laws and policies by means of new indicators and data regarding minor subjects, PDUs and arrested dealers. <i>Carla Rossi, Italy</i> – Implications of monitoring alcohol marketing for public health and policy. <i>Carina Ferreira-Borges, Portugal</i> 	<ul style="list-style-type: none"> – New psychoactive substance use among regular psychostimulant users in Australia, 2010-2017. <i>Rachel Sutherland, Australia</i> – New trends in drug use in Germany? The use of new psychoactive substances and methamphetamine in five federal states. <i>Elena Gomes de Matos, Germany</i> – The EU early warning system – 20 years of monitoring new psychoactive substances in Europe. <i>Rachel Christie, EMCDDA</i> – New psychoactive substances (NPS) in Portugal – trends and approaches. <i>Susana Henriques, Portugal</i> – Teenagers and NPS in Poland – attitudes and behaviors. <i>Tomasz Biatas, Poland</i> 	<ul style="list-style-type: none"> – The problem with ‘responsible gambling’: a study of attitudes towards and experiences of personal responsibility discourses in people experiencing gambling addiction. <i>Helen Miller, Australia</i> – Learning from success: the implementation and scientific evaluation of the Israeli national comprehensive program to reduce alcohol problem drinking among children and youth 2010-2016. <i>Yossi Harel-Fisch, Israel</i> – Online prevention of substance abuse among students with eCHUG-D. <i>Marion Laging, Germany</i> – Prevention systems in Europe: how can they be described, assessed and improved. <i>Gregor Burkhart, EMCDDA</i> – High school finalists trip: preventing risk behaviour with young people. <i>Irma Brito, Portugal</i> 	<ul style="list-style-type: none"> – Multi-setting community-based interventions to reduce population level harms arising from alcohol and other drug use. <i>Emily Stockings, Australia</i> – Successful application of a cross-sectoral integrated care approach to addiction and homeless services – the experience from southern Ireland. <i>Joe Kirby, Ireland</i> – Efficacy of case management for persons with substance use disorders: a Cochrane update. Wouter Vanderplasschen, Belgium – Heplink: integrating hepatitis C treatment in primary care. <i>Walter Cullen, Ireland</i> – Exploring fast track opiate agonist treatment (OAT) for homeless, American, opiate mis-users. <i>Marcia Tanur, United States</i> – The new privatized market for alcohol and drug treatment – growing challenges in regard to inconsistent principles and fumbling steering models. <i>Jessica Storbjörk, Sweden</i>
STRUCTURED SESSION 10 Biomarkers in addiction: the experience of the Spanish network on addiction research Chair: <i>Fernando Rodriguez de Fonseca, Spain</i>	STRUCTURED SESSION 11 Lessons learned from the recent HIV outbreaks in Europe among people who inject drugs Chair: <i>Don Des Jarlais, United States and Vana Sypsa, Greece</i>	STRUCTURED SESSION 12 Addiction in daily life: mobile assessment and treatment Chair: <i>Ingmar Franken, Netherlands</i>	
<ul style="list-style-type: none"> <i>Marta Torrens, Spain</i> <i>Marta Rodriguez-Arias, Spain</i> <i>Maribel Colado, Spain</i> <i>Olga Valverde, Spain</i> – Titles to be confirmed. 	<ul style="list-style-type: none"> – Lessons learned from the recent snow blow related HIV outbreak in Dublin. <i>Margaret Fitzgerald, Ireland</i> – The HIV outbreak among PWID in Romania 2012-2016. <i>Cristina Fierbinteanu, Romania</i> – An outbreak of HIV infection among people who inject drugs in Glasgow (United Kingdom). <i>Andrew McAuley and Catriona Milosevic, United Kingdom</i> – An outbreak of HIV infection among people who inject drugs in Athens, 	<ul style="list-style-type: none"> – EMA in the field of addiction. <i>Joel Swendsen, France</i> – Cognitive measures in EMA research. <i>Andy Jones, United Kingdom</i> – The use of EMA in a clinical trial. Ilse Verveer, Netherlands – Smartphone apps for the treatment of addictive disorders. <i>Yasser Khazaal, Switzerland</i> Discussants: <i>Ingmar Franken, Netherlands and Matt Field, United Kingdom</i> 	

Greece: rapid intervention and lessons learned. *Vana Sypsa, Greece*
 – Injection of cocaine is associated with recent HIV outbreak in People Who Inject Drugs in Luxembourg. *Carole Devaux, Luxembourg*

16:00 – 16:30

Coffee break

16:30 – 18:00 **PARALLEL SESSIONS** (see separate document for poster sessions)

PAPER SESSION 18 Moving interventions online	PAPER SESSION 19 A focus on methodology	PAPER SESSION 20 Basic science - new findings	PAPER SESSION 21 Alcohol - issues for treatment	PAPER SESSION 22 Local perspectives - local responses
<ul style="list-style-type: none"> – Online problem gamblers’ motivation to change: a qualitative study with implications for the design of online interventions. <i>Ayna Johansen, Norway</i> – Assessing readiness to implement web-based interventions for the prevention and/or reduction of substance use at ten universities in Germany – results of the DIOS-project. <i>Claudia Pischke, Germany</i> – Characteristics of gamblers using a national help-line for problem gambling in France between 2010 and 2015. <i>Stéphane Darbeda, France</i> – YouTube presence of an addiction medicine service: what works? <i>Gerard Calzada, Switzerland</i> 	<ul style="list-style-type: none"> – Estimating alcohol annual consumption on the basis of population survey. <i>Janusz Sieroslawski, Poland</i> – Beyond informed consent: ethical dilemmas in a clinical trial testing the effectiveness of injectable opioid assisted treatment for long-term opioid dependence. <i>Kirsten Marchand, Canada</i> – Different modes of data collection, different results. <i>Clara Vital, Portugal</i> – The absurdity of asking the people about opinions they do not yet have. Alfred Uhl, Austria – Ethical inquiry into cannabis pilot projects. <i>Susanne Uusitalo, Finland</i> – The use of licit and illicit drugs and the workplace: defining a model of survey questionnaire. <i>Cláudia Urbano, Portugal</i> 	<ul style="list-style-type: none"> – Alteration to hippocampal volume and shape in cannabis dependence: a multisite study. <i>Yann Chye, Australia</i> – Weighing the evidence: a systematic review on long-term neurocognitive effects of cannabis use in abstinent adolescents and adults. <i>Florian Ganzer, Germany</i> – Locomotor sensitization to cocaine and methamphetamine in drosophila melanogaster. <i>Rozi Andretic Waldowski, Croatia</i> – Using functional near infrared spectroscopy to identify neural activity during cue-elicited in a real-life setting. <i>Flora Colledge, Switzerland</i> – Accumulation of highly stable δfosb-isoforms and its targets inside the reward system of chronic drug abusers. <i>Monika Seltenhammer, Austria</i> – Dependent anabolic-androgenic steroid users have larger nucleus accumbens volume and thinner cortex compared to non-dependent users. <i>Lisa Evju Hauger, Norway</i> 	<ul style="list-style-type: none"> – Is dialectical behavior therapy skills training a therapeutic alternative in alcohol use disorder and personality disorders comorbidity treatment? <i>Marco Cavicchioli, Italy</i> – Will this adult patient go into severe alcohol withdrawal? Systematic review and meta-analysis. <i>Jan Klimas, Ireland</i> – Outpatient addiction treatment for alcohol use disorder: what makes patients who dropped out different from those who did not? <i>Vincent Wagner, France</i> – Effectiveness of brief intervention for moderate/high risk alcohol use among patients on buprenorphine maintenance: a clinical and alcohol-biomarker study. <i>Suresh Thapaliya, Nepal</i> – Characteristics and significance of professional-led support groups in the treatment of alcoholism. <i>Ana Opačić, Croatia</i> – Improving the identification and treatment of problem drug and alcohol users in somatic healthcare - a cross-sectional comparative study. <i>Danil Gamboa, Norway</i> 	<ul style="list-style-type: none"> – Peer education ‘youth for youth’. <i>Zrinka Puharić, Croatia</i> – Drug addiction in Senegal, the case of Casamance. <i>Benoît Tine, Senegal</i> – Why getting sober isn’t enough? Multiple addictions among the hard to reach population in the ‘largest open drug scene’ in Israel. <i>Hagit Bonny-Noach, Israel</i> – Interaction and interplay between rapid assessment and a local drug monitor. <i>Liv Flesland, Norway</i> – Public expenditure on drug treatment and associated comorbidities: the case-study of Bergamo. <i>Sabrina Molinaro, Italy</i>

STRUCTURED SESSION 13 Anabolic androgenic steroids (AAS) and associated drugs: new insights into the extent of use, harms and responses Chair: <i>James McVeigh, United Kingdom</i>	STRUCTURED SESSION 14 Advancing theory and treatment approaches for males in substance use treatment who perpetrate intimate partner violence Chair: <i>Gail Gilchrist, United Kingdom</i>	STRUCTURED SESSION 15 Prevalence of alcohol, tobacco and drug use in the mediterranean region among school aged children - the MEDSPAD network Chair: <i>Richard Muscat, Malta</i>	STRUCTURED SESSION 16 The future of addiction research: discussion Chair: <i>Robert West, United Kingdom</i>	STRUCTURED SESSION 17 Attune: understanding pathways to stimulant use: a mixed-methods examination of the individual, social and cultural factors shaping illicit stimulant use across Europe Chair: <i>Marcus Martens, Germany</i>
<ul style="list-style-type: none"> – AAS and substance use among prisoners: findings from a Norwegian national prison Survey. <i>Ingrid Havnes, Norway</i> – A typology of AAS use by men in fitness and strength-training environments. <i>Dimitris Liokaftos, Denmark</i> – An investigation of cognitive functions in long-term AAS using and non-using weightlifters. <i>Astrid Bjørnebekk, Norway</i> – Injection related harms and infections among people injecting AAS and associated drugs in the United Kingdom. <i>Vivian Hope, United Kingdom</i> – Treatment and information needs among AAS users with health problems. <i>Christine Wisløff, Norway</i> Discussion: <i>Marie-Claire Van Hout, United Kingdom.</i>	<ul style="list-style-type: none"> – Meta-ethnography of 24 qualitative studies to describe the role that substance use may play in IPV perpetration. <i>Fay Dennis, United Kingdom</i> – Qualitative interviews conducted in England describing 45 substance-using perpetrators’ and their ex/current-partners’ narratives of what contributes to IPV. <i>Polly Radcliffe, United Kingdom</i> – Systematic review of effective interventions to reduce IPV perpetration among male substance users and what works for whom. <i>Danielle Stephens-Lewis and Amy Johnson, United Kingdom</i> 	<ul style="list-style-type: none"> – MedSPAD Network history. <i>Florence Mabileau, Pompidou Group</i> – MedSPAD Regional key findings. <i>Valeria Siciliano, Italy</i> – MedSPAD Regional key findings. <i>Elisa Benedetti, Germany</i> – Legal, social and economic aspects that impact on prevalence. <i>Salah Abdennouri, Algeria, Menan Rabie, Egypt, Yossi Harel-Fisch, Israel, Jallal Toufiq, Morocco, and Hajer Aounallah-Skhiri, Tunisia</i> Discussion Panel: <i>Meni Malliori, Greece, Florence Mabileau, Pompidou Group, Valeria Siciliano, Italy, and Richard Muscat, Malta</i>	<ul style="list-style-type: none"> – Details to be confirmed. 	<ul style="list-style-type: none"> – Introduction to the EU ATTUNE study: an overview of the mixed method design and its rationale. <i>Marcus Martens, Germany</i> – Which individual, social and environmental influences shape different pathways of amphetamine type stimulant use over the life course? A systematic review and thematic synthesis of the qualitative literature. <i>Amy O’Donnell and Michelle Addison, United Kingdom</i> – ATS users’ experiences of transitions into diverse patterns of stimulant use: results from in-depth qualitative interviews in five EU countries. <i>Roman Gabrhelik, Czech Republic, Heike Zurhold, Netherlands and Michal Szulawski, Poland</i> – Exploring trajectories of amphetamine use from the life event and substance use charts applied in qualitative interviews with stimulant and non-stimulant users. <i>Nienke Liebrechts, Netherlands and Katrin Schiffer, Netherlands</i> – Design, methods and instruments of the forthcoming quantitative study arm: structured questionnaire of 2000 ATS users across Europe. <i>Magdalena Rowicka, Poland and Moritz Rosenkranz, Germany</i>

18:00

Conference Cocktail

09:00 – 10:30 **PLENARY SESSION II MEASURING ADDICTIONS – A QUESTION OF SCALE**

Chair: *Sabrina Molinaro, Italy*

Global burden of addictions. *Louisa Degenhardt, Australia*

Addiction-related crime and 'harms to the society'. *Letizia Paoli, Belgium*

Opioids and other drug issues. *Christopher Jones, United States*

10:30 – 11:00

Coffee break

11:00 – 12:30 **PARALLEL SESSIONS** (see separate document for poster sessions)

PAPER SESSION 23	PAPER SESSION 24	PAPER SESSION 25	PAPER SESSION 26	PAPER SESSION 27
Cannabis - shifts in the regulatory framework	Understanding drug-related mortality	Alcohol - targeting the young	Improving responses to opioid users and PWID	Market developments and their impact
<ul style="list-style-type: none"> – Understanding the new cannabis regulatory frameworks. <i>Ivana Obradovic, France</i> – Relation of legalization of cannabis for medical purposes and adolescent use in the United States. <i>William Crano, United States</i> – Cannabis as medicine in Germany. <i>Ingo Ilja Michels, Germany</i> – Worldwide drug use decriminalization practices: a scoping review. <i>Marta Pinto, Portugal</i> – A work in progress: understanding the development of the cannabis social club model in Belgium and its current key features. <i>Mafalda Pardal, Belgium</i> – Investigating regulatory 	<ul style="list-style-type: none"> – Trends in injector deaths in Ireland, as recorded by the national drugs-related deaths index, 1998-2014. <i>Therese Lynn, Ireland</i> – Mortality and causes of death in the Norwegian national OMT-programme in the years 2014 and 2015. <i>Anne Bech, Norway</i> – Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. <i>Marica Ferri, EMCDDA</i> – Opioid overdose mortality trends in Australia. <i>Amanda Roxburgh, Australia</i> – Mortality and causes of death among polydrug users. <i>Karoliina Karjalainen, Finland</i> – Rates, causes and predictors of 	<ul style="list-style-type: none"> – Attentional bias between light and heavy drinking college students. <i>Alexandra Ghita, Spain</i> – Energy drink and alcohol mixed energy drink use among high school adolescents: association with risk taking behavior, social characteristics. <i>Sabrina Molinaro, Italy</i> – Sensation seeking and adolescent alcohol use: exploring the mediating role of unstructured socializing with peers. <i>Sharon Sznitman, Israel</i> – Prevention of alcohol abuse in college students. <i>Carla Rocha, Portugal</i> – Alcohol: raising awareness and action research on heavy episodic drinking among low income youth and young adults in southern Europe. <i>Helena Carvalho, Portugal</i> – Associations between personal and 	<ul style="list-style-type: none"> – Establishing a postal based harm reduction service for hard-to-reach injecting drug users. <i>Thomas Nefau, France</i> – Documenting barriers to access HCV care and treatment: a peer-led research. <i>João Santa Maria, Portugal</i> – Diagnosis and treatment of HCV infection: a tool of engagement for people who inject drugs (PWID). <i>Brian Conway, Canada</i> – Evaluating the impact of opioid substitution treatment on mortality – a CPRD cohort study comparing community prescribing of buprenorphine and methadone in United Kingdom. <i>Matthew Hickman, United Kingdom</i> – The German medical association's revised guidelines for OST: legal framework, treatment regulations and scientific rationale. <i>Wilfried Kunstmann, Germany</i> – Towards a long-term perspective: 	<ul style="list-style-type: none"> – To use or not to use? An exploration of cannabis use motives and constraints. <i>Liz Temple, Australia</i> – Are changes in cannabis potency associated with subsequent admissions to drug treatment? <i>Tom Freeman, United Kingdom</i> – The displacement of illicit drug markets from the Netherlands to Belgium: perception or reality? <i>Freja de Middelmeer, Belgium</i> – Impact of the change in poppers regulation on their use in France. <i>Cécile Chevallier, France</i> – A dramatic increase in cannabis use among young and adult populations in Israel: the 'normalization' effects of the intense public debates regarding cannabis legalization and medicalization. <i>Yossi Harel-Fisch, Israel</i> – User characteristics and effect

<p>approaches to medicinal and recreational cannabis. <i>Chris Wilkins, New Zealand</i></p>	<p>death among drug users in France: invisibility of fatal overdoses. <i>Anne-Claire Brisacier, France</i></p> <p>– Rates, characteristics and circumstances of methamphetamine-related deaths: a national 7 year study. <i>Shane Darke, Australia</i></p>	<p>perceived peer use and attitudes towards substance use among German university students- findings of a multi-centre cluster-controlled intervention trial. <i>Stefanie Maria Helmer, Germany</i></p>	<p>analysis of treatment participation in opioid substitution therapy in four European regions. <i>Carlos Nordt, Switzerland</i></p> <p>– The German legal system and the regulatory approach governing the substitution treatment for opioid addicts in Germany - regulations at the federal level: the revision of Germany's legal framework. <i>Kenan Maric-Horstmeier, Germany</i></p>	<p>profiles of butane hash oil: an extremely high-potency cannabis concentrate. <i>Gary Chan, Australia</i></p> <p>– Violence, fraud, legal risks and avoidance strategies in small-scale drug markets. Results from social research in Germany. <i>Bernd Werse, Germany</i></p>
---	--	---	--	--

<p>STRUCTURED SESSION 18</p> <p>20 years of ESPAD: trends in adolescents' substance use and risk behaviours, what have we learnt? Chair: <i>Julian Vicente, EMCDDA</i></p>	<p>STRUCTURED SESSION 19</p> <p>How the opioid problem is changing: the role of misused medicines and the emergence of novel synthetic opioids Chair: <i>Paul Griffiths, EMCDDA and Moira O'Brien, NIDA</i></p>	<p>STRUCTURED SESSION 20</p> <p>Wastewater-based drug epidemiology of illicit drugs, new psychoactive substances and the misuse of medication as a supplement to traditional data-sources Chair: <i>Barbara Kasprzyk-Hordern, United Kingdom</i></p>
<ul style="list-style-type: none"> – Are the times a-changin'? Trends in adolescent substance use in Europe. <i>Ludwig Kraus, Germany</i> – Is there a link between perceived availability and use of alcohol, cannabis and cigarettes among young people in Europe - cross-country and within country analyses of the 2015 ESPAD-data. <i>Håkan Leifman, Sweden</i> – Students at risk of substance use: Latent class risk and protective factor profiles. <i>Pavla Chomynova, Czech Republic</i> – Understanding the use of NPS by European students in the context of polysubstance use. <i>Harry Sumnall, United Kingdom</i> – Do misusers of medicinal psychotropic drugs form a distinctive group among the adolescent-student population in Europe? A latent class analysis. <i>Anastasios Fotiou, Greece</i> – Gambling, online gaming and illicit substance use among European students: A cross-national comparison. <i>Sabrina Molinaro, Italy</i> 	<ul style="list-style-type: none"> – Misuse of prescription opioids in Europe: an overview of evidence and how it relates to prescribing practice from a European perspective. <i>Cathy Stannard, United Kingdom</i> – The US opioid epidemic: a perspective on trends and responses from the U.S. National Drug Early Warning System. <i>Erin Artigiani, United States</i> – Australian experience with opioids. <i>Michael Farrell, Australia</i> – New synthetic opioids in Europe: perspective from the EU Early Warning System. <i>Rita Jorge, EMCDDA</i> 	<ul style="list-style-type: none"> – Review of the existing European network with summary of all data, and overview of future international programs. <i>Kevin Thomas, Australia</i> – Comparison of data from WBE with other sources: A summary of findings. <i>Frederic Been, Belgium</i> – Detection of New Psychoactive Substances (NPS) use across Europe. <i>Sara Castiglioni, Italy</i> – The use of WBE for the detection of the misuse of medication. <i>Jørgen Bramness, Norway</i> – Review of the uncertainties in WBE. <i>Christoph Ort, Switzerland</i>

STRUCTURED SESSION 21 Online surveys of drug users: proceed with caution Chair: <i>Beau Kilmer, United States</i>	STRUCTURED SESSION 22 Political and ethical implications of the brain disease model of addiction Chair: <i>Matilda Hellman, Finland</i>	STRUCTURED SESSION 23 Reconceptualizing the etiology of substance use: implications for prevention and treatment Chair: <i>Gregor Burkhardt, EMCDDA</i>
<ul style="list-style-type: none"> – European Web Survey on Drugs: patterns of use. <i>Nicola Singleton and João Matias, EMCDDA</i> – Facebook ads for recruitment for online drug surveys: the Holy Grail? <i>Dijana Jerković, Croatia</i> – The Global Drug Survey (GDS): How online methods and independence offer alternative perspectives on drug use. <i>Adam Winstock, United Kingdom and Larissa Meier, Switzerland</i> – Reliability and validity issues in European web survey in Czech Republic. <i>Katerina Skarupova, Czech Republic</i> – Estimating cannabis demand: use of online surveys to capture use patterns. <i>Margriet van Laar, Netherlands</i> 	<ul style="list-style-type: none"> – Concepts and ideas on addiction: a historical perspective on great mergers. <i>Johan Edman, Sweden</i> – Popular promises of progress: the articulation of BDMA in the media. <i>Anna Alanko and Matilda Hellman, Finland</i> – The BDMA: Ethical and epistemological questions and considerations. <i>Jaakko Kuorikoski and Susanne Uusitalo, Finland</i> – Gambling and the brain. <i>Janne Nikkinen, Finland</i> 	<ul style="list-style-type: none"> – Panel discussion: <i>Zili Sloboda, United States</i> <i>Diana Fishbein, United States</i> <i>Alessandro Pirona, EMCDDA</i> <i>Gilberto Gerra, UNODC</i>

12:45 – 14:15 SPONSORED SESSIONS

Lunch boxes available between 12:30 and 14:30

12:45 – 14:15 PARALLEL SESSIONS (see separate document for poster sessions)

PAPER SESSION 28 Spotlight on the misuse of medicines	PAPER SESSION 29 New methods	PAPER SESSION 30 Focus on pregnancy and the neonate	PAPER SESSION 31 Drug use and migration
<ul style="list-style-type: none"> – A case study of anabolic-androgenic steroid dependence and treatment experiences. <i>Ingrid Havnes and Johan Nygaard, Norway</i> – Is misuse of benzodiazepines among high-risk drug users an overlooked public health issue? <i>Dominique Lopez, India</i> – Medication use and misuse among illicit drug users in France. <i>Aurélie Lermenier-Jeannet, France</i> – Gabapentin diversion and misuse in the United States from a law enforcement perspective: diversion rates 2002-2015 and 	<ul style="list-style-type: none"> – New perspectives for knowledge generation and exploitation using web surveys: the example of volume estimation in wastewater epidemiology. <i>Robin Udrisard, Switzerland</i> – High risk drug use and new psychoactive substances in Europe. <i>Jane Mounteney, EMCDDA</i> – National estimation of the prevalence of problem drug use: revisiting and extending multiplier methods in a multi-parameter evidence synthesis framework. <i>Hayley Jones, United Kingdom</i> 	<ul style="list-style-type: none"> – Follow up of opioid exposed newborns until 3 years of age. <i>Anna Maria Vella, Malta</i> – Alcohol drinking in pregnancy: some predictors among Portuguese women. <i>Ludmila Carapinha, Portugal</i> – Cannabis use during pregnancy and risk of adverse birth outcomes: a longitudinal cohort study. <i>Svetlana Skurtveit, Norway</i> – Neonatal outcomes after fetal exposure to opioid maintenance treatment. <i>Blanka Nechanska, Czech Republic</i> 	<ul style="list-style-type: none"> – Can you develop problems with khat? Cross-sectional and longitudinal studies to determine the potential for clinically meaningful khat use disorder and withdrawal syndromes. <i>Raimondo Bruno, Australia</i> – Social profiles, drug use practices and HCV exposure of Russian-speaking migrants in France. <i>Marie Jauffret-Roustide, France</i> – How ethnic is social recovery in problem users with a migration background. <i>Charlotte de Kock, Belgium</i>

<p>qualitative research findings. <i>Mance Buttram, United States</i></p>	<ul style="list-style-type: none"> – United States national drug early warning system (NDEWS): evolving drug early warning systems in a new world of drug production, distribution, and use. <i>Erin Artigiani, United States</i> – Development of a national wastewater drug monitoring program in Australia. <i>Jake O'Brien, Australia</i> 		
<p>STRUCTURED SESSION 24 Take-home-naloxone: taking drug users seriously <i>Chair: Thomas Clausen, Norway</i></p>	<p>STRUCTURED SESSION 25 No one gets left behind: addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community in Dublin, Ireland <i>Chair: John Lambert, Ireland</i></p>	<p>STRUCTURED SESSION 26 Targeting hard-to-reach client groups for addiction aid in Switzerland - good practice in international perspective <i>Chair: Petra Baumberger, Switzerland</i></p>	<p>STRUCTURED SESSION 27 Voices from the margins <i>Chair: Sarah Galvani, United Kingdom</i></p>
<ul style="list-style-type: none"> – Overdose deaths; diverging trends among heterogeneous groups of victims. <i>Isabelle Giraudon, EMCDDA</i> – New non-injectable naloxone products: global overview. <i>Rebecca McDonald, United Kingdom</i> – Experiences from a national overdose prevention strategy; nasal naloxone distribution and lessons learned. <i>Desiree Madah-Amiri, Norway</i> – Opt-out vs opt-in: should take-home-naloxone be required as a safe clinical practice? <i>John Strang, United Kingdom</i> – Take home naloxone as integral part of toolkits for public health providers; priorities across settings. <i>Dagmar Hedrich, EMCDDA</i> – Drug user's experience with take-home-naloxone; 'how I saved my friend'; Short film 	<ul style="list-style-type: none"> – HepCheck: To enhance HCV screening of PWID. <i>Geoff McCombe, Ireland</i> – HepLink: To integrate primary and secondary care by developing an integrated model of HCV care for PWID. <i>Davina Swan, Ireland</i> – Hepfriend: Developing and cost evaluating a community peer support model to improve access to HCV treatments for PWID. <i>Nicola Perry, Ireland</i> 	<ul style="list-style-type: none"> – Improvement of the support for addicted persons' relatives – Recommendations. <i>Petra Baumberger, Switzerland</i> – Hard-to-reach target groups in addiction aid – What efforts are already taken and what need for action remains? <i>Stefanie Knocks, Switzerland</i> – SafeZone.ch – online counselling on addiction. <i>Salomé Steinle, Switzerland</i> – Indebtedness process among problematic gamblers. <i>Oscar Ruiz, Switzerland</i> 	<ul style="list-style-type: none"> – Transitions to long term recovery: developing identities and sustainable change. <i>Jo Ashby, United Kingdom</i> – Developing methodological identities: co-production in addiction research. <i>Lucy Webb, United Kingdom</i> – New psychoactive substances, new drug user identities and new service provider challenges. <i>Rob Ralphs, United Kingdom</i> – Who supports dying substance users? Drug using identities and end of life care. <i>Sarah Galvani, United Kingdom</i>

14:30 – 16:00 **PARALLEL SESSIONS** (see separate document for poster sessions)

PAPER SESSION 32 The constructs of addiction	PAPER SESSION 33 Evaluating impact	PAPER SESSION 34 Developing effective drug treatment	PAPER SESSION 35 Perspectives on harm reduction	PAPER SESSION 36 Responding in the prison setting
<ul style="list-style-type: none"> – Emotion regulation, attachment and addictive behaviors. <i>Paula Jauregui, Spain</i> – Implicit associations in male and female gamers across four different online games are linked to symptoms of internet gaming disorder. <i>Christian Laier, Germany</i> – Psychological and neurobiological mechanisms underlying the addictive use of specific internet applications. <i>Matthias Brand, Germany</i> – Implicit association and craving towards shopping cues in buying disorder. <i>Patrick Trotzke, Germany</i> 	<ul style="list-style-type: none"> – The evaluation of the alcohol law 2009 in Belgium. <i>Tina Van Havere, Belgium</i> – The effect of criminal sanction on new psychoactive substance supply reduction: a realist synthesis. <i>Minqi Zhao, China</i> – Adaption of the assist model of informal peer-led intervention delivery to the talk to frank drug prevention programme in United Kingdom secondary schools (ASSIST+FRANK): a pilot cluster randomised controlled trial. <i>James White, United Kingdom</i> – Assessment of drug treatment in Croatia - results from cats (Croatian addiction treatment survey) and its implication on new national drug policy strategy. <i>Zrinka Cavar, Croatia</i> – An approach to disinvestment in the field of drug abuse. <i>Antonella Camposeragna, Italy</i> 	<ul style="list-style-type: none"> – What is the base for evidence-based treatment of opioid dependence? A systematic review of outcomes from longitudinal observational studies. <i>Lucas Wiessing, EMCDDA</i> – Extrinsic and intrinsic factors in drug treatment outcomes for persons in the criminal justice system: the roles of motivation and legal coercion. <i>Steven Belenko, United States</i> – Reasons for abstaining in persons with long-term substance use disorders: a qualitative study. <i>Henning Pettersen, Norway</i> – Utilisation of specialist psychiatric health care services - 15 years follow-up of a Norwegian OMT-cohort. <i>Bent Monsbakken, Norway</i> – Profiles of individuals identified as having a substance use disorder and types of services received. <i>Serge Brochu, Canada</i> – Does exposure to opioid substitution treatment at prison release reduce the risk of death? A prospective, observational study in England. <i>Matthew Hickman, United Kingdom</i> 	<ul style="list-style-type: none"> – Take-home naloxone: pharmacokinetics of a novel nasal spray in development in Europe. <i>Rebecca McDonald, United Kingdom</i> – Residential eviction and syringe sharing among a prospective cohort of street-involved youth. <i>Andreas Pilarinos, Canada</i> – The needle exchange debate in Stockholm city council and Swedish parliament during the 21st century. <i>Lena Eriksson, Sweden</i> – The acceptability and feasibility of a brief psychosocial intervention to reduce blood borne virus risk behaviours among people who inject drugs: a randomised control feasibility trial of a psychosocial intervention. <i>Gail Gilchrist, United Kingdom</i> – The cost-effectiveness of needle and syringe provision in preventing transmission of hepatitis C virus in people who inject drugs. <i>Zoe Ward, United Kingdom</i> – Evaluation of a drug checking integrated service: boom festival 2016. <i>Helena Valente, Portugal</i> 	<ul style="list-style-type: none"> – Anger management in detained addicts for prevention of both crime and drug use: a controlled cognitive behavioral trial in an attenuate custody prison: a preliminary study. <i>Felice Nava, Italy</i> – Drug use in prison: the role of peer educators (8 years of intervention in a Portuguese prison setting). <i>Andreia Nisa, Portugal</i> – Estimating the potential impact of providing HIV treatment and opioid agonist therapy (OAT) in prison and upon release on HIV incidence among people who inject drugs (PWID) in Tijuana, Mexico. <i>Annick Borquez, United States</i> – Modelling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky. <i>Jack Stone, United Kingdom</i> – The use of NPS in prison in Europe: what do we know? Consequences and responses. <i>Linda Montanari, EMCDDA</i> – Prison as a point of care for hepatitis c: recommendations based on strategic analysis of population dynamics/ uptake of screening in prisons in England and Wales. <i>Nat Wright, United Kingdom</i> – Assessing the social acceptability of harm reduction scale-up in French prison settings: results from the ANRS-pride research. <i>Marie Jauffret-Roustide, France</i>

STRUCTURED SESSION 28 Advancing hepatitis C care in people with a history of injecting drugs/ opioid use disorder (OUD) Chair: <i>Carlos Roncero, Spain</i>	STRUCTURED SESSION 29 Harm reduction for people who inject drugs in Europe: findings from three major European projects Chair: <i>Mika Salminen, Finland</i>	STRUCTURED SESSION 30 Review of the effectiveness of treatment alternatives to incarceration for drug-involved persons Chair: <i>Roger Peters, United States</i>	STRUCTURED SESSION 31 Health and social responses to drug problems in Europe: current state-of-the-art and future opportunities Chair: <i>Wayne Hall, Australia</i>
<ul style="list-style-type: none"> – Assessing the size of populations with injecting drug risk for chronic HCV infection. <i>Jens Reimer, Germany</i> – Barriers to treatment for HCV in OUD. What matters most? <i>Nat Wright, United Kingdom</i> – Practical steps for HCV care in OUD populations: Results of a program to develop a best practice guide. <i>Carlos Roncero, Spain</i> – A vision for HCV and OUD in Europe. What should the overall strategy look like? <i>Lorenzo Somaini, Italy</i> 	<ul style="list-style-type: none"> – HIV/HCV testing within low-threshold services. <i>Alexandra Gurinova, Germany</i> – Health outcomes for clients of needle and syringe programs in prisons: a systematic review. <i>Heino Stöver, Germany</i> – No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community. <i>John Lambert, Ireland</i> – Community HIV testing in PWID: data from the COBATEST network. <i>Laura Fernandez Lopez, Spain</i> – Pilot condom distribution in a Czech prison. <i>Viktor Mravcik, Czech Republic</i> – Harm reduction availability and accessibility in Europe – survey. <i>Jeffrey Lazarus, Denmark</i> 	<ul style="list-style-type: none"> – Inter-American Drug Abuse Control Commission (CICAD) support to national and local governments in establishing drug treatment courts in Central and South America. <i>Antonio Lomba, United States</i> – The Portuguese system of community reintegration of drug-involved offenders from 1998 until 2015. <i>João Pedro Augusto, Portugal</i> – Incarceration of drug-involved offenders in the Czech Republic and in Europe, and need for treatment-based alternatives. <i>Michal Miovský, Czech Republic</i> – Alternatives to incarceration developed through TASC programs in the U.S. <i>Melody Heaps, United States</i> – Review of the effectiveness of treatment alternatives to incarceration for drug-involved persons. <i>Roger Peters, United States</i> 	<ul style="list-style-type: none"> – Panel discussion: <i>Nicola Singleton, EMCDDA</i> <i>Dagmar Hedrich, EMCDDA</i> <i>Marica Ferri, EMCDDA</i> <i>Alessandro Pirona, EMCDDA</i> <i>Harry Sumnall, United Kingdom</i>

16:00 – 16:30 **Coffee break**

16:30 – 18:00 **PLENARY SESSION III BOUNDARIES OF ADDICTION**

Chair: *Catherine Comiskey, Ireland*

Social construction of addiction. *Henri Bergeron, France*

New vistas in basic, preclinical and translational addiction research. *Rainer Spanagel, Germany*

Economic and conflict based rapid mass population movement into Europe: the security and public health implications for future EU drugs policy. *Marie-Claire Van Hout, United Kingdom*

2017 EMCDDA Scientific award ceremony

18:30 **Conference dinner** (pre-booking required)

09:00 – 10:30 **PLENARY SESSION IV CHALLENGES AHEAD**

Chair: Kerstin Stenius, Finland

Extending definitions in addiction *Joël Billieux, Luxembourg*

Challenges ahead for tobacco policies *Ann McNeil, United Kingdom*

Challenges ahead for cannabis policies *Beau Kilmer, United States*

10:30 – 11:00

Coffee break

11:00 – 12:30 **PARALLEL SESSIONS** (see separate document for poster sessions)

PAPER SESSION 37	PAPER SESSION 38	PAPER SESSION 39	PAPER SESSION 40	PAPER SESSION 41
Illuminating the darknet and online markets	Gambling – assessment	Understanding health consequences	Innovations in practice	The importance of gender
<ul style="list-style-type: none"> – Forensic drug intelligence and the rise of darknet marketplaces. <i>Marie Morelato, Australia</i> – Four years of monitoring cryptomarkets on the darknet. <i>Amanda Roxburgh, Australia</i> – “This place is like the jungle”. Discussion about NPS on a cryptomarket. <i>Sara Rolando, Italy</i> – Purity, adulteration and price of drugs bought on-line versus off-line in the Netherlands. <i>Peggy van der Pol, Netherlands</i> – The role of the ‘dark web’ in the trade of illicit drugs and the role of the Netherlands on these marketplaces. <i>Kristy Kruithof, United Kingdom</i> 	<ul style="list-style-type: none"> – Association of problem gambling with type of gambling. <i>Marco Scalese, Italy</i> – Parents, peers, or promotion? <i>Hannah Pitt, Australia</i> – Role of emotion dysregulation as a predictor of pathological gambling and comorbid disorders. <i>Paula Jauregui, Spain</i> – Trajectories of gambling behaviour and gambling problems in outpatient care – results from an ongoing study. <i>Ludwig Kraus, Germany</i> – Gambling in Croatia (pilot project counties). <i>Zrinka Puharić, Croatia</i> – Core gambling-related traits and their relationships with gambling behavior patterns and severity: an exploratory study with Ecuadorian gamblers. <i>Maria Fernanda Jara Rizzo, Spain</i> 	<ul style="list-style-type: none"> – The use of alcohol and drugs and its relation to the workplace. <i>Cláudia Urbano, Portugal</i> – Cognitive bias modification targeting the cannabis and alcohol consumption of youth in juvenile detention centers. <i>Hans van der Baan, Netherlands</i> – One-year sobriety improves satisfaction with life, executive functions and psychological distress among patients with polysubstance use disorder. <i>Egon Hagen, Norway</i> – What can 20,000 people tell us about their recent nitrous oxide (N2O) use? Understanding the recreational use of N2O and the dose-response relationship with myeloneuropathy. <i>Jason Ferris, Australia</i> – Making cannabis safer: striking the balance between THC and CBD. <i>Amir Englund, United Kingdom</i> 	<ul style="list-style-type: none"> – Experiential avoidance and emotional dysregulation as therapeutic dimensions in alcohol use disorder treatment: findings based on 3-months dialectical behavior therapy skills training. <i>Marco Cavicchioli, Italy</i> – Clinical strategies for engaging families of patients in substance addiction treatment programs: results from an exploratory study with leading family therapists in the United States. <i>Sebastian Perumbilly, United States</i> – Building a bridge between prevention research and practice: conclusions from the long-term development and implementation of the rebound life skills and drug education programme. <i>Maximilian von Heyden, Germany</i> – Development of therapeutic alliance and outcomes from the perspective of drug users undergoing treatment in a therapeutic community. <i>Luís Janeiro, Portugal</i> 	<ul style="list-style-type: none"> – Insecure attachment and female drug use. <i>Efrat Fridman, United States</i> – Intimate partner violence in the past 12 months among men receiving treatment for substance use: prevalence, men’s explanations and substances used at the time of the incident. <i>Martha Canfield, United Kingdom</i> – Men’s and women’s response to treatment in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder. <i>Heather Palis, Canada</i> – The prevalence and factors associated with ever perpetrating intimate partner violence by men receiving substance use treatment in Brazil and England: a cross-cultural comparison. <i>Gail Gilchrist, United Kingdom</i> – Experiences and barriers of female drug users on alcohol and drug prevention and treatment in Belgium. <i>Julie Schamp, Belgium</i>

	<p>– Symptoms and correlates of emergency medical treatment following the use of MDMA (2014-2016). <i>Larissa Maier, Switzerland</i></p>		<p>– Suicidal ideation among long-term opioid users: its risk factors and the role of gender. <i>Kirsten Marchand, Canada</i> – Opioid using pregnant Maltese women. <i>Anna Maria Vella, Malta</i></p>
<p>STRUCTURED SESSION 32 Promoting a new era in global training and education of addiction professionals: the international consortium of universities for drug demand reduction Chair: <i>Michal Miovský, Czech Republic</i></p>	<p>STRUCTURED SESSION 33 Drug treatment expenditure: methodological insights on proper measurement Chair: <i>Anne Line Breteville-Jensen, Norway</i></p>	<p>STRUCTURED SESSION 34 Why are there more drug-related deaths: challenges for monitoring, understanding and preventing – examples from Europe Chair: <i>Isabelle Giraudon, EMCDDA</i></p>	<p>STRUCTURED SESSION 35 Addressing the unmet reproductive health needs of women with addiction Chair: <i>Jan-Peter Siedentopf, Germany</i></p>
<p>– Panel discussion: <i>Brian A. Morales, United States</i> <i>Melody M. Heaps, United States</i> <i>Roger H. Peters, United States</i> <i>Zili Sloboda, United States</i> <i>Jeff Lee, United Kingdom</i> <i>Amalie Pavlovská, Czech Republic</i></p> <p>– Titles to be confirmed.</p>	<p>– A methodology for estimating health expenditure on drug treatment: the Australian experience. <i>Alison Ritter, Australia</i> – Estimating the costs of substitution therapy for heroin and opioid addiction in the United States: Insights and challenges. <i>Rosalie Pacula, United States</i> – A methodology for an EU cross-country comparison: public expenditure on drug treatment in hospitals. <i>Freya Vander Laenen, Belgium</i> – Social cost in France: What’s new if the field of death toll and illness calculations. <i>Pierre Kopp, France</i> Discussant: <i>Cláudia Costa Storti, EMCDDA</i></p>	<p>– Setting the European scene: Drug-related deaths in Europe: rebound and shifts? Brief update on a diverse picture. <i>Isabelle Giraudon, EMCDDA</i> – A review of triggers and drivers of drug-related deaths in seven northern European countries. <i>Tim Millar and Andrew Mc Auley, United Kingdom</i> – Estimations of trends, effects of changes in recording practices and studies of drug pattern. Focus on Sweden. <i>Håkan Leifman, Sweden</i> – Preventing drug-related deaths: Policy implications and ways forward. Focus on Norway. <i>Thomas Clausen, Norway</i> – A different perspective from Australia. <i>Shane Darke, Australia</i></p>	<p>– Panel discussion: <i>Mary Hepburn, United Kingdom</i> <i>Natanya Robinowitz, United States</i> <i>Mishka Terplan, United States</i></p> <p>– Titles to be confirmed.</p>
<p>STRUCTURED SESSION 36 Anonymous collecting and testing of NPS samples as a part of national early warning systems (EWS) Chair: <i>Simona Šabić, Slovenia</i></p> <p>– Anonymous collection and testing of NPS samples as a part of national EWS: challenges and advantages. <i>Andreja Drev, Slovenia</i> – Establishment of NGO info points for NPS sample collection within regional EWS system in the framework of I-SEE project. <i>Ada Hočevar Grom, Slovenia</i></p>	<p>STRUCTURED SESSION 37 Best practices in HCV prevention, management and treatment among people who inject drugs Chair: <i>Alexis Goosdeel, EMCDDA</i> and <i>Matthew Hickman, United Kingdom</i></p> <p>– Model and empirical evidence on the effectiveness of interventions to prevent HCV among people who inject drugs. <i>Matthew Hickman, United Kingdom</i> – Direct-acting interferon-free therapies and reinfection among people who inject drugs. <i>Jason Grebely, Australia</i></p>	<p>STRUCTURED SESSION 38 Drug research and drug monitoring in prison Chair: <i>Heino Stöver, WEPHREN</i> and <i>Linda Montanari, EMCDDA</i></p> <p>– WHO minimum public health data set on prison health. <i>Lars Møller, WHO-Regional Office for Europe</i> – European Questionnaire on Drug Use among Prisoners – EQDP. <i>Viktor Mravcik, Czech Republic</i></p>	

- The integrated drug checking service and its importance for different types of users. *Simona Šabić, Slovenia*
- Establishment of drug checking service in MSM community: things to be considered. *Miran Šolinc, Slovenia (tbc)*

- Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe. *Jeffrey Lazarus, Denmark*

- Prison history - drug-related problems in people who inject drugs. *Lucas Wiessing, EMCDDA*
- Spanish survey on health and drug use among prisoners. *Elena Alavarez, Spain*
- Monitoring drug use in custodial institutions for juvenile offenders in Portugal. *Ludmila Carapinha, Portugal*
- French system on drug monitoring in prison. *Marie Jauffret-Roustide, France*

Lunch boxes available between 12:30 and 14:30

12:45 – 14:15 PARALLEL SESSIONS (see separate document for poster sessions)

PAPER SESSION 42

Spotlight on drug consumption rooms

- Drug consumption rooms: issues of social and political acceptability in French public debate. *Marie Jauffret-Roustide, France*
- Influencing drug policy: making the case for medically supervised injecting facilities in Dublin. *Tony Duffin, Ireland*
- Drug consumption rooms in Porto, Portugal: listening to the concerned voices. *Paula Meireles, Portugal*
- Frequency and severity of non-fatal opioid overdoses among clients attending the Sydney medically supervised injecting centre. *Amanda Roxburgh, Australia*
- Drug consumption rooms in Catalonia: major impact on HIV-HCV risk behaviors and engagement in care. *Cinta Folch, Spain*
- Factors concerning access to a potential drug consumption room in Dublin, Ireland. *Emma Atkin-Brenninkmeyer, Ireland*

PAPER SESSION 43

Analysis to inform service development and delivery

- Screening of drug use in primary care services in Catalonia, feasibility analysis of the assist tool. *Joan Colom i Farran, Spain*
- Improving treatment outcome by adding different structural elements to outpatient substance abuse treatment programs offered to Danish youth. *Mads Uffe Pedersen and Sheila Jones, Denmark*
- The Portuguese DSM-IV-MR-J: validation of an instrument to measure youth problem gambling to the Portuguese language. *Joana Alexandre, Portugal*
- Evaluating the integration of indigenous healing practices with principles of seeking safety for treatment of indigenous patients with a history of trauma and active substance use disorder. *Teresa Marsh, Canada*
- The efficacy of mindfulness-based treatments for alcohol and drugs use disorders: a critical meta-analytic review of randomized and non-randomized controlled trials. *Marco Cavicchioli, Italy*

PAPER SESSION 44

Improving the evidence base on HCV

- Detachable low dead-space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, England: an economic evaluation. *Peter Vickerman, United Kingdom*
- Early HCV treatment and HCV case finding in people who inject drugs (PWID): cost-effectiveness studies. *Matthew Hickman, United Kingdom*
- HCV treatment as prevention in Europe: model projections and impact of current and scaled-up treatment rates. *Hannah Fraser, United Kingdom*
- Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe. *Jeffrey Lazarus, Denmark*

STRUCTURED SESSION 39 The stigma of addiction and its impacts on healthcare. Chair: <i>Karsten Lunze, United States</i>	STRUCTURED SESSION 40 Ayahuasca – why is classification so important? Chair: <i>Mário Simões, Portugal</i>	STRUCTURED SESSION 41 Prevention: from evidence to action – how we are working. Chair: <i>Joaquim Fonseca, Portugal</i>	STRUCTURED SESSION 42 The universal prevention curriculum (UPC) adaptation in Europe: introduction and discussion on substantial content. Chair: <i>Annemie Coone, Belgium</i>	STRUCTURED SESSION 43 Promoting the use of evidence-based programmes in Europe: a European registry. Chair: <i>Gregor Burkhart, EMCDDA</i>
<ul style="list-style-type: none"> – Stigma among people who use drugs. <i>Jason Luoma, Valerie Earnshaw and Patrick Corrigan, United States</i> – The stigma of unhealthy alcohol use. <i>Georg Schomerus and Nicolas Rüschi, United States</i> – Understanding and intervening on addiction stigma. <i>Magdalena Kozena and Karsten Lunze, United States</i> 	<ul style="list-style-type: none"> – Ethnical uses of Ayahuasca. <i>Tania Re, Italy and Jorge Martins, Portugal</i> – Ayahuasca’s therapeutic potential in drug addiction. <i>Mário Simões and José Palma, Portugal</i> – Pharmacology of Ayahuasca. <i>Olga Silva, Portugal</i> – Ayahuasca uncertain legal status. <i>Sofia Machado, Portugal</i> 	<ul style="list-style-type: none"> – School-based drug use prevention multicomponent model: a Lisbon and Tagus Valley Region Perspective. <i>Isabel Prata, Portugal</i> – ‘Me and the Others’ programme: building standards-based narratives for prevention. <i>Raúl Melo, Portugal</i> – ‘Me and Others’ Programme – Outcome Evaluation: Lisbon and Tagus Valley Region sample (2015 to 2017). Pre, post and follow up. <i>Carla Frazão, Portugal</i> – ‘Guidelines to deal with addictive behaviours’. Project, process and outcome evaluation. <i>Rui Pedro Silva, Portugal</i> 	<ul style="list-style-type: none"> – Why is a common training curriculum for Europe needed? <i>Annemie Coone, Belgium</i> – Getting to the UPC-curriculum and projecting this content on the participants own context. <i>Sanela Talic, Slovenia, Katarzina Okulicz, Poland, and Maria Antónia Gomila, Spain</i> – Substance use prevention training needs found in the involved countries and local prevention training needs of the participants. <i>Annemie Coone, Belgium and Antónia Katarzyna Okulicz, Poland</i> 	<ul style="list-style-type: none"> – Panel discussion: <i>Marica Ferri, EMCDDA Gregor Burkhart, EMCDDA Frederick Groeger-Roth, Germany Nick Axford, United Kingdom Shreya Sonthalia, United Kingdom Fabrizio Faggiano, Italy Zili Sloboda, United States</i>

14:30 – 16:00 PARALLEL SESSIONS (see separate document for poster sessions)

PAPER SESSION 45 Interconnected problems - spotlight on comorbidity	PAPER SESSION 46 Innovative methods	PAPER SESSION 47 Gambling – informing interventions	PAPER SESSION 48 Innovation in harm reduction	PAPER SESSION 49 The challenge of responding in recreational settings
<ul style="list-style-type: none"> – Is problematic internet use associated with general psychological distress in young people? Findings from an Italian representative sample of digital natives. <i>Valeria Siciliano, Italy</i> – Investigating possible causal associations of tobacco and cannabis use with mental health: a Mendelian randomisation analysis. <i>Meg Fluharty, United Kingdom</i> 	<ul style="list-style-type: none"> – Wastewater analysis: source of information about the relation between frequently abused illicit drugs and music genre preferences. <i>Paula Brandeburová, Slovakia</i> – Representativeness challenges for web surveys collecting information on drug users: a way for improving the cannabis market estimation in France. <i>François Beck, France</i> 	<ul style="list-style-type: none"> – Documenting the strategies and tactics used by the Australian gambling industry. A case study of clubs, casinos and the wagering industry. <i>Samantha Thomas, Australia</i> – Stigma and the involvement of people with gambling addiction in peer support and advocacy activities. <i>Helen Miller, Australia</i> 	<ul style="list-style-type: none"> – Illegal and legal substance abuse amongst harm reduction program users - a case study from Croatia. <i>Dalibor Dolezal, Croatia</i> – Drug checking - an approach to prevent chemical anarchy: a scoping review. <i>Helena Valente, Portugal</i> – Chemsex, NPS and risk reduction management: preliminary results of a pilot study. <i>Cécile Chevallier, France</i> 	<ul style="list-style-type: none"> – Social representations of drugs and drug abuse. Inquiry to the Portuguese youth present in three editions of Rock in Rio summer festival (2008/2012/2016). <i>Vasco Calado, Portugal</i> – Stop SV: staff training on prevention of sexual violence. <i>Fernando Mendes, Portugal</i>

<ul style="list-style-type: none"> – Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders. <i>Kristine Rømer Thomsen, Denmark</i> – Sex differences in psychiatric disorders among illicit drug users. <i>Gail Gilchrist, United Kingdom</i> – Alcohol- and drug-related problems among adolescents with psychiatric diagnoses: the role of psychiatric comorbidity. <i>Ove Heradstveit, Norway</i> – Father involvement and correlates of symptoms of depression and anxiety among fathers with drug addiction problems. <i>João Barrocas, Portugal</i> 	<ul style="list-style-type: none"> – The European drug emergencies network (Euro-DEN) project – a model for European data collection on acute drug and new psychoactive substance (NPS) toxicity. <i>Paul Dargan, United Kingdom</i> – The analysis of illicit drugs in Sydney wastewater. <i>Anne Bannwarth, Switzerland</i> – Temporal trends and subjective highness for alternative cannabis product use reported in an online cannabis community. <i>Meredith Meacham, United States</i> 	<ul style="list-style-type: none"> – The role of gambling advocacy strategies in gambling harm prevention and minimisation strategies. <i>Jennifer David, Australia</i> – Parents, peers, or promotion? Which factors are the most influential in shaping children’s attitudes towards gambling? <i>Hannah Pitt, Australia</i> – Jegspiller.no – a new prevention tool for problems related to gambling and gaming. <i>Jarle Wangen, Norway</i> – Maladaptive metacognitive beliefs in pathological gambling: relationship with addictive behaviors and comorbid symptomatology. <i>Paula Jauregui, Spain</i> 	<ul style="list-style-type: none"> – Harm reduction 24/7: the supply of harm reduction materials via vending machines for drug users in Northrhine-Westfalia, Germany. <i>Daniel Deimel, Germany</i> – Disciplining pleasure through harm reduction policy: confronting drug users’ personal experience of injection in context with professionals’ public health expectations. <i>Marie Jauffret-Roustide, France</i> – Alcohol consumption among party goers attending university parties. Samples from three years of harm reduction interventions in the field (2014 to 2016 in the region of Lisbon and Tagus valley). <i>Marta Borges, Portugal</i> 	<ul style="list-style-type: none"> – A randomized trial of assessment interventions to reduce drug use and HIV/STI sexual risk among young adults who use drugs in the club scene. <i>Steven Kurtz, United States</i> – How often do ecstasy users in nightlife implement harm reduction strategies? <i>Peggy van der Pol, Netherlands</i> – Health consequences of substance use in nightlife settings in the Netherlands. <i>Karin Monshouwer, Netherlands</i>
--	--	---	--	---

<p>STRUCTURED SESSION 44</p> <p>Nightlife: no risk no fun? challenges for drug prevention and trendspotting</p> <p>Chair: <i>Gregor Burkhardt, EMCDDA</i></p>	<p>STRUCTURED SESSION 45</p> <p>Continuum of care in the prison setting? Responses to drug-related infection transmission in prisons – examples from Europe</p> <p>Chair: <i>Dagmar Hedrich, EMCDDA</i></p>	<p>STRUCTURED SESSION 46</p> <p>Crystal meth and the family – stress, strain, and interventions</p> <p>Chair: <i>Michael Klein, Germany</i></p>	<p>STRUCTURED SESSION 47</p> <p>Multidisciplinary work in a scientific society of addictions</p> <p>Chair: <i>Francisco Pascual, Spain</i></p>	<p>STRUCTURED SESSION 48</p> <p>GRADE evidence to decision framework for the EMCDDA Best practice portal</p> <p>Chair: <i>Elena Parmelli, Italy</i></p>
--	--	--	---	--

<ul style="list-style-type: none"> – Drug use in European recreational settings: mixing contexts, risks and pleasure. <i>João Matias, EMCDDA</i> – Environmental prevention in nightlife settings. <i>Johanna Gripenberg, Sweden</i> – Protecting and promoting health in nightlife environments during the last three decades. <i>Andrew Bennett, United Kingdom</i> – Zurich’s integrated nightlife approach. <i>Alexander Büchel, Switzerland</i> 	<ul style="list-style-type: none"> – Drug use and drug-related infections among prisoners. <i>Linda Montanari, EMCDDA</i> – Access to harm reduction – the example of France. <i>Laurent Michel, France</i> – Access to HCV treatment under special consideration in prisons – action research Austria. <i>Gabriele Fischer, Austria</i> – New joint European guidance on responding to communicable diseases in prison – focus on drug use-related infections. <i>Lara Tavooschi, Sweden</i> 	<ul style="list-style-type: none"> – Establishing an integrated perinatal care program for substance-dependent young mothers. <i>Ulrich Zimmermann, Germany</i> – Living situation of children from methamphetamine-involved families. <i>Michael Klein, Germany</i> – Parenting stress and familial coping in the context of parental methamphetamine use. <i>Janina Dyba, Germany</i> – SHIFT – A parenting intervention for methamphetamine abusing mothers and fathers. <i>Diana Moesgen, Germany</i> 	<ul style="list-style-type: none"> – A sociological study on alcohol and cannabis use among young people in Spain. <i>Gerardo Florez, Spain</i> – Socidrogalcohol Spanish national survey on prevalence and treatment of co-occurrence of substance use disorder and other mental health disorder. <i>Juan José Fernández, Spain</i> – The RINCA Study Study on the Reduction of Negative Incidences associated to excessive Alcohol 	<ul style="list-style-type: none"> – The Best practice portal. <i>Marica Ferri, EMCDDA</i> – The DECIDE Project. <i>Marina Davoli, Italy</i> – A practical example of application of the GRADE EtD framework to a Best practice portal topic. <i>Elena Parmelli, Italy</i>
--	---	---	---	---

<p>– Emerging trends within nightlife settings: responses and innovation. <i>Sarah Morton, Ireland</i></p>		<p>– Treatment of methamphetamine addicts in clinical practice. <i>Katharina Schoett, Germany</i></p>	<p>Consumption. <i>Josep Guardia, Spain</i></p>	
--	--	---	---	--

16:00 – 16:30 Coffee break

16:30 Closing session, including closing keynote

ORGANISERS



INTERNATIONAL ORGANISATIONS



COLLABORATIVE PARTNERS



SUPPORTING ORGANIZATIONS

